Ligand id: 8709

Name: ozanimod

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 104.2
Molecular weight 404.18
XLogP 3.73
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Ozanimod has reached Phase III clinical trial for its potential antiinflammatory effects in relapsing multiple sclerosis and ulcerative colitis.
Mechanism Of Action and Pharmacodynamic Effects
S1PR1 modulation selectively and reversibly promotes sequestration of circulating lymphocytes in peripheral lymphoid tissue by modulating lymphocyte trafficking. Importantly, this action inhibitis migration of autoreactive lymphocytes to areas of disease inflammation, which is a major contributor to autoimmune disease. S1PR1 modulation may also reduce lymphocyte migration into the central nervous system (CNS), where some indicated disease processes take place. This therapeutic approach downregulates the pathological effects of autoreactive lymphocytes which underly the autoimmune diseases being investigated in clinical trials of ozanimod, but may also be a useful strategy for other autoimmune conditions.